Influenza Immunization for Adult and Pediatric Patients Undergoing Cancer Treatment
Organization: Alberta Health ServicesPublished: 2017
"In a given year, between 10% and 20% of the Canadian population becomes infected with influenza, and an estimated 12,200 hospitalizations and 3,500 deaths can be attributed to an epidemic of influenza; these include deaths related to pneumonia due to influenza virus or a secondary pathogen like Streptococcus pneumonia. Rates of influenza infection are highest in children between the ages of five and nine years, but rates of serious illness and death are highest in children under the age of two years, older persons (>65 years), and persons with underlying medical conditions. Adult and pediatric patients with cancer are considered immunosuppressed, either as a result of their underlying disease or secondary to their treatment, and are therefore included in this high risk group. Influenza infection not only causes primary illness but also can lead to severe secondary medical complications, including viral pneumonia, secondary bacterial pneumonia, and worsening of underlying medical conditions". - Influenza Immunization for Adult and Pediatric Patients Undergoing Cancer Treatment
Product Type: Guide
Category:
Specific Populations,High Risk Adults,High Risk Children,Vaccine Preventable Diseases,Communicable Diseases,Influenza Specific PopulationsHigh Risk Adults
High Risk Children
Vaccine Preventable Diseases
Communicable Diseases
Influenza
Population: High Risk Adults
High Risk Children
Region: Alberta (AB)
Resource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.